Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|15|12|1166-1175

ISSN： 1389-4501

Source： Current Drug Targets, Vol.15, Iss.12, 2014-11, pp. : 1166-1175

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Triple-Negative Breast Cancer: Epidemiology and Management Options

By Dawood Shaheenah  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2247-2258

Adis International

Access to resources Recommend Favorite

Subtyping of triple-negative breast cancer: Implications for therapy

By Abramson Vandana G.   Lehmann Brian D.   Ballinger Tarah J.   Pietenpol Jennifer A.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 8-16

Blackwell Publishing

Access to resources Recommend Favorite

Advances in the Treatment of Triple-negative Early Breast Cancer

By  

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors

By Medioni Jacques   Huchon Cyrille   >  

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 147-157

Adis International

Access to resources Recommend Favorite

Genomics-Based Prognosis and Therapeutic Prediction in Breast Cancer

By Jeffrey Stefanie S.   Lønning Per Eystein   Hillner Bruce E.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 3, 2005-05 ,pp. : 291-300

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite